Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press104810.17650/1726-9776-2008-4-4-74-79DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряGemcitabine (Citochem) in the treatment of advanced transitional cell bladder cancerГемцитабин (Цитогем®) в лечении распространенного переходно-клеточного рака мочевого пузыряMatveyevV. B.МатвеевВ. Б.
Russian Federation

Department of urology

Moscow

Отделение урологии

г. Москва

VolkovaM. I.ВолковаМ. И.
Russian Federation

Department of urology

Moscow

Отделение урологии

г. Москва

State Enterprise N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН301220084474791302202013022020https://oncourology.abvpress.ru/oncur/article/view/1048

Citochem is an effective and safe medication: main active substrate of the agent is gemcitabine. Citochem in combination with cisplatin provides satisfactory efficacy without high toxicity of treatment in patients with advanced transitional cell bladder cancer and can be recommended for use in clinical practice of oncourology.

.

1. Huang P., Chubb S., Hertel L.W. et al. Action of 2’,2’-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51(22):6110—7.Huang P., Chubb S., Hertel L.W. et al. Action of 2’,2’-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51(22):6110—7.2. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2’,2’-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993;46(4):762—6.Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2’,2’-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993;46(4):762—6.3. Guchelaar H.J., Richel D.J., van Knapen A. Clinical, toxicological and pharmacological aspects of Gemcitabine. Cancer Treat Rev 1996;22(1):15—31.Guchelaar H.J., Richel D.J., van Knapen A. Clinical, toxicological and pharmacological aspects of Gemcitabine. Cancer Treat Rev 1996;22(1):15—31.4. Storniolo A.M., Allerheiligen S.R., Pearce H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24(2 Suppl 7):2—7.Storniolo A.M., Allerheiligen S.R., Pearce H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24(2 Suppl 7):2—7.5. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М.: Вердана, 2001.Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М.: Вердана, 2001.6. Регистр лекарственных средств России. Энциклопедия лекарств. Ежегодный сборник, вып. 9. Под ред. Г.Л. Вышковского. М.: РЛС — 2000, 2002.Регистр лекарственных средств России. Энциклопедия лекарств. Ежегодный сборник, вып. 9. Под ред. Г.Л. Вышковского. М.: РЛС — 2000, 2002.7. Sternberg C.N., Yagoda A., Scher H.I. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448—58.Sternberg C.N., Yagoda A., Scher H.I. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448—58.8. Saxman S., Propert K., Einhorn L. et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial cancer. A cooperative group study. J Clin Oncol 1997;15:2564—9.Saxman S., Propert K., Einhorn L. et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial cancer. A cooperative group study. J Clin Oncol 1997;15:2564—9.9. Pollera C.F., Ceribelli A., Crecco M. et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from phase I study. Ann Oncol 1994;5:182—4.Pollera C.F., Ceribelli A., Crecco M. et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from phase I study. Ann Oncol 1994;5:182—4.10. DeLena M., Gridelli C., Lorusso V. et al. Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cance (abstr). Proc ASCO 1996;15:246.DeLena M., Gridelli C., Lorusso V. et al. Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cance (abstr). Proc ASCO 1996;15:246.11. Stadler W.M., Kuzel T.M., Roth B. et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394—8.Stadler W.M., Kuzel T.M., Roth B. et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394—8.12. Moore M.J., Tannock I.F., Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441—5.Moore M.J., Tannock I.F., Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441—5.13. Lorusso V., Pollera C.F., Antimi M. et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur J Cancer 1998;34(8):1208—12.Lorusso V., Pollera C.F., Antimi M. et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur J Cancer 1998;34(8):1208—12.14. Kaufman D., Stadler W., Carducci M. et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCQ: final results of a phase II study. Proc ASCO 1998;17:320a. Abstr 1235.Kaufman D., Stadler W., Carducci M. et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCQ: final results of a phase II study. Proc ASCO 1998;17:320a. Abstr 1235.15. Mancarella S., Lorusso V., Manzione L. et al. Gemcitabine/ cisplatin in advanced transitional cell carcinoma of the urinary tract (TCQ: a phase II multicemer trial. Eur J Cancer 1999;35(Suppl 4):347. Abstr 1405.Mancarella S., Lorusso V., Manzione L. et al. Gemcitabine/ cisplatin in advanced transitional cell carcinoma of the urinary tract (TCQ: a phase II multicemer trial. Eur J Cancer 1999;35(Suppl 4):347. Abstr 1405.16. Moore J.M., Winquist E.W., Murray N. et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Clin Oncol 1999;17:2876—81.Moore J.M., Winquist E.W., Murray N. et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Clin Oncol 1999;17:2876—81.17. Von der Maase H., Hansen S.W., Roberts J.T. et. al. Gemcitabine and cisplatin versus MVAC in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068—77.Von der Maase H., Hansen S.W., Roberts J.T. et. al. Gemcitabine and cisplatin versus MVAC in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068—77.18. Bellmunt J., Guillem V., Paz-Ares L. et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitionalcell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247.Bellmunt J., Guillem V., Paz-Ares L. et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitionalcell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247.19. Hussain M., Vaishampayan U., Du W. et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527.Hussain M., Vaishampayan U., Du W. et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527.20. Ramirez A., Maroto P., Gallego H. et al. Carboplatin (CBDCA) gemcitabine (GEM) as first-line therapy for advanced transitional cell carcinoma (TCC) of the urinary tract. Feasibility in patients with moderate to severe renal failure. Single center experience. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting; May 18—21, 2002; Orlando, Florida. Abstr 795.Ramirez A., Maroto P., Gallego H. et al. Carboplatin (CBDCA) gemcitabine (GEM) as first-line therapy for advanced transitional cell carcinoma (TCC) of the urinary tract. Feasibility in patients with moderate to severe renal failure. Single center experience. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting; May 18—21, 2002; Orlando, Florida. Abstr 795.21. Carles J., Nogue M., Domenech M. et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the Bladder and impaired renal function. Oncology 2000;59(1):24—7.Carles J., Nogue M., Domenech M. et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the Bladder and impaired renal function. Oncology 2000;59(1):24—7.22. Meluch A.A., Greco F.A., Burris H.A. III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018.Meluch A.A., Greco F.A., Burris H.A. III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018.23. Sternberg C.N., Calabro F., Pizzocaro G. et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993.Sternberg C.N., Calabro F., Pizzocaro G. et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993.24. Bruni G.C., Posca T., Celiento G. Gemcitabine and Navelbine in elderly patients with bladder cancer: a pilot study. Ann Oncol 1998;9(Suppl 4):64.Bruni G.C., Posca T., Celiento G. Gemcitabine and Navelbine in elderly patients with bladder cancer: a pilot study. Ann Oncol 1998;9(Suppl 4):64.25. Caristi N., Maisano R., Spadaro P. et al. Gemcitabine and vinorelbine in combination in patients older than 70 years or unresponsive to a cisplatin chemotherapy in advanced bladder cancer. Proc ASCO 2000;19:362a. Abstr 1429.Caristi N., Maisano R., Spadaro P. et al. Gemcitabine and vinorelbine in combination in patients older than 70 years or unresponsive to a cisplatin chemotherapy in advanced bladder cancer. Proc ASCO 2000;19:362a. Abstr 1429.26. Neri B., Cini G., Doni L. et al. Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 2002;87(5):497—501.Neri B., Cini G., Doni L. et al. Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 2002;87(5):497—501.27. Dalbagni G., Russo P., Bochner B. et al. Phase II trial of intravesical gemcitabine in bacille calmette-guОrin-refractory transitional cell carcinoma of the Bladder. J Clin Oncol 2006;24(18):2729—34.Dalbagni G., Russo P., Bochner B. et al. Phase II trial of intravesical gemcitabine in bacille calmette-guОrin-refractory transitional cell carcinoma of the Bladder. J Clin Oncol 2006;24(18):2729—34.